About Biocartis Group NV

Company Description

Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for COVID-19, flu, RSV and sepsis.

Biocartis’ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.

Year founded

2007

Served area

Worldwide

Headcount

500

Shareholder information

Shares outstanding

92,989,699

IPO

April 27, 2015

Stock exchange(s)

Euronext Brussels

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.